03/20/23 7:00 AMNasdaq : ABVC low floatABVC BioPharma Provides Vitargus® Update on Phase II Site Initiation Visit Conducted at Srinagarind Hospital in ThailandABVC BioPharma, Inc., a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Vitargus ® Phase II Site Initiation Visit at Srinagarind Hospital, Khon Kaen University was successfully conducted on March 9-10, 2023. ABVC BioPharma Provides Vitargus ® Update on...RHEA-AIneutral
03/14/23 7:00 AMNasdaq : ABVC low floatABVC BioPharma Receives Registration Approval for Maitake Mushroom Dietary Supplement by the Taiwan Ministry of Health and WelfareABVC Biopharma, Inc. ("ABVC" or the "Company") (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that BioKey, a wholly-owned subsidiary of theRHEA-AIvery positive
02/28/23 8:30 AMNasdaq : ABVC low floatABVC BioPharma Provides 2023 Pipeline Update via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today provided an update to drug and medical device developmentsRHEA-AIneutral
02/23/23 4:16 PMNasdaq : ABVC clinical triallow floatABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trialsvia NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it has closed a funding agreement for gross proceedsRHEA-AIneutral
02/21/23 8:30 AMNasdaq : ABVC low floatABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus® ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that approval to initiate the Phase II study of itsRHEA-AIvery positive
01/19/23 8:30 AMNasdaq : ABVC low floatABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conferencevia NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Dr. Keith McBurnett, Professor of Psychiatry atRHEA-AIneutral
01/05/23 8:30 AMNasdaq : ABVC clinical trialfda approvallow floatFDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancervia NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology today announced that the US Food & Drug Administration notified theRHEA-AIneutral
11/17/22 8:30 AMNasdaq : ABVC fda approvallow floatABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approvalvia NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Vitargus® Phase II Clinical Study ProtocolRHEA-AIneutral
11/14/22 6:20 PMNasdaq : ABVC low floatABVC BioPharma Reports Third Quarter 2022 Financial and Operational Resultsvia NewMediaWire – ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced its financial and operating results for the thirdRHEA-AIneutral
11/07/22 8:30 AMNasdaq : ABVC low floatABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD)via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that on October 20, 2022, it received a Notice ofRHEA-AIneutral